Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of CD19+ non-Hodgkin's lymphoma or chronic lymphocytic leukemia

- Primary refractory or multiply relapsed (after at least 2 prior chemotherapy
regimens) disease

- Ineligible for bone marrow or peripheral blood stem cell transplantation

PATIENT CHARACTERISTICS:

Age:

- Over 18

Performance status:

- ECOG 0-2

Life expectancy:

- More than 3 months

Hematopoietic:

- WBC greater than 3,000/mm^3

- Platelet count greater than 100,000/mm^3

- Absolute neutrophil count greater than 1,500/mm^3

Hepatic:

- Bilirubin less than 1.5 mg/dL

- Alkaline phosphatase less than 2 times normal

- SGPT less than 2 times normal

Renal:

- Creatinine clearance greater than 50 mL/min

Other:

- No human-anti-murine-antibody response to prior murine monoclonal antibodies

- No immunological or inflammatory disease (e.g., lupus erythematosus)

- No active serious infection

- No other serious medical condition that would limit survival to less than 2 years

- No other active malignancy except non-melanoma skin cancer or carcinoma in situ of
the cervix

- No psychiatric or addictive disorder that would preclude study

- Not pregnant or nursing

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Prior immunotherapy allowed

Chemotherapy:

- See Disease Characteristics

- No concurrent chemotherapy

Endocrine therapy:

- Concurrent steroids for adrenal failure or adverse reactions to study drug allowed

- Concurrent hormonal therapy for non-disease related conditions (e.g., insulin for
diabetes) allowed

Radiotherapy:

- Not specified

Surgery:

- Not specified